Last reviewed · How we verify
TIO
Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic M3 receptors in airway smooth muscle to produce sustained airway relaxation.
Tiotropium is a long-acting anticholinergic bronchodilator that blocks muscarinic M3 receptors in airway smooth muscle to produce sustained airway relaxation. Used for Chronic obstructive pulmonary disease (COPD) maintenance treatment, Asthma maintenance treatment (in combination with inhaled corticosteroids).
At a glance
| Generic name | TIO |
|---|---|
| Also known as | Spiriva® |
| Sponsor | GlaxoSmithKline |
| Drug class | Long-acting muscarinic antagonist (LAMA) |
| Target | Muscarinic M3 receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory / Pulmonology |
| Phase | FDA-approved |
Mechanism of action
Tiotropium binds to muscarinic M3 receptors on airway smooth muscle cells, preventing acetylcholine-induced bronchoconstriction. This results in sustained bronchodilation lasting 24 hours or longer, allowing once-daily dosing. The drug is inhaled directly to the lungs, providing local therapeutic effect with minimal systemic exposure.
Approved indications
- Chronic obstructive pulmonary disease (COPD) maintenance treatment
- Asthma maintenance treatment (in combination with inhaled corticosteroids)
Common side effects
- Dry mouth
- Tremor
- Headache
- Urinary retention
- Constipation
Key clinical trials
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma (PHASE3)
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders (PHASE2)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT (PHASE2)
- Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS (PHASE2, PHASE3)
- Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant (PHASE2)
- Ability of Pupillometry to Reduce Sufentanil Consumption in Planned Cardiac Surgery: Randomized, Controlled, Single-center Clinical Superiority Trial (NA)
- Al18F-NOTA-LM3 PET/CT in Patients With TIO (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |